RE:VPH CEOTotally agree with you. Valeo is cheap right now considering the nature of the business (No R&D risk), the growing pipeline, an experience team that owns 75% of the cie (because they put their money on the table, not because they got free warrants), many new drugs coming to market in Q3-Q4 2020. Also huge revenu grow in the next 12 months, probably 3 to 5X with generic heparin that will start to sell in the next few weeks. The team is working non stop to search for new drugs already approved and sold in USA and Europe for years (no risk). Also, very important to notice that 4 canadian province including BC are now obligated by law to buy generic drug when available, meaning Valeo generic Heparin sell will ramp up very fast there and with covid19, government dept skyrocketed, so I would not be surprised that all the other provinces mainly Quebec and Ontario will pass a law for generic product to be bought first. For Heparin only, it is 200 million market in Canada and Valeo is the only ''generic Heparin'' available in Canada, so a lot of potential there. And as you say, it is without counting the benefic side of heparin for Covid19 that could help boost the sell further more. YES, Valo is still under the radar and very cheap considering the forecast increase revenu for the next 12 months and further and all the rest.
I also suggest you another MULTIPLE X upside cie (IMHO): Ortho regenerative technologie,
C.ORTH https://www.orthorti.com/ This is an R&D cie, so yes it is more risky, but if you take 10 minutes to read what they are working on on their website, you will understand that it is not so risky and the upside potential in the next 24 months is a possible 20X or more.
I believe they will start their phase 1 clinical trial for rotary cuff repair next quarter.